Veradermics stock jumps again on female hair loss drug win

This is the second positive Phase II readout of VDPHL01, which analysts note could represent a $2bn+ market opportunity This is the second positive Phase II readout of VDPHL01, which analysts note could represent a $2bn+ market opportunity If approved, it could become the first oral medication for female hair loss. Credit: Pormezz / Shutterstock.com Veradermics has seen another jump in its stock price as its hair loss drug showed benefit in women with androgenetic alopecia (AGA). In a Phase II trial (NCT06527365), female patients treated with VDPHL01 achieved consistent hair growth on the endpoint of non-vellus target area hair…

Source: Clinical Trials Arena